Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027
Benzinga Newsdesk 4 days ago
News
33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12Low
- 33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12
- From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12
- Low discontinuation rates, and favorable safety and tolerability observed across placebo and treatment groups, with no serious adverse events assessed as related to study treatment
- Study has achieved 75% enrollment, with 90 patients randomized to date; on track to report topline data in 2027
AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF).
